Previous 10 | Next 10 |
Exelixis (NASDAQ: EXEL ) is scheduled to announce Q2 earnings results on Thursday, August 6th, after market close. The consensus EPS Estimate is $0.12 (-58.6% Y/Y) and the consensus Revenue Estimate is $226.4M (-5.8% Y/Y). Over the last 2 years, EXEL has beaten EPS estimates 100% of ...
FinancialBuzz.com News Commentary New York, NY (7/31/2020) – According to the World Health Organization, cancer is the leading cause of mortality globally, accounting for approximately 9.6 million deaths in 2018. The three key categories of drugs used for cancer, based on their mechanis...
– Conference Call and Webcast to Follow at 5:30 p.m. EDT / 2:30 p.m. PDT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 after the markets close. At 5:30 p.m. EDT / 2:30 p.m. PDT...
Osmotica Pharmaceuticals receives PDUFA date Osmotica Pharmaceuticals Plc ( OSMT ) reported that the FDA has set December 29, 2020 as the PDUFA date for arbaclofen extended release (ER) tablets. The company also stated that the regulatory body considered its resubmission to the NDA for t...
Exelixis (NASDAQ: EXEL ) has initiated CONTACT-03 , a global phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) in patients with inoperable, locally advanced or metastatic renal cell carcinoma (RCC) who progressed during or following trea...
– CONTACT-03 is the third of three phase 3 pivotal trials that are part of a clinical collaboration with Roche – Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 pivotal trial of cabozantinib (CABOMETYX ® ) in combinati...
The market has been on a roll over the past few weeks. Since late March, all three major U.S. market indexes are up by more than 30%. However, we are still facing a grim economic outlook, and investors shouldn't disregard the possibility of another market crash. Since it always pays to be ready...
Although stock market corrections are part of the investing cycle, no investor, tenured or not, could have been prepared for what 2020 has offered. In about a four-month time span, the stock market has crammed in about a decade's worth of volatility -- and the coronavirus disease 2019 (COVID-19)...
( Pexels ) Of all the investable sectors and industries, one of the top-performing over the past few months is biotechnology. Since its March low (18 th ), the SPDR Biotech ETF ( XBI ) has risen about 75% as investors speculate on virus treatment and vaccine rumors. Understandably, many in...
Revance Therapeutics Reports Positive Results from Facial Skin Trial Revance Therapeutics ( RVNC ) reported positive data from its two Phase 2a clinical trials. Both the trials indicated that DaxibotulinumtoxinA or DAXI is efficacious as well as well tolerated. The first study sought to ...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...